Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Sell at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Monday, Wall Street Zen reports.

Several other research analysts have also recently issued reports on EPRX. Stifel Nicolaus set a $25.00 price objective on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Wedbush initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. HC Wainwright upped their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. Finally, Oppenheimer restated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Get Our Latest Research Report on Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock opened at $8.15 on Monday. The business’s fifty day simple moving average is $7.64 and its 200-day simple moving average is $7.24. Eupraxia Pharmaceuticals has a 12-month low of $5.63 and a 12-month high of $9.32. The company has a market cap of $548.02 million, a PE ratio of -7.69 and a beta of 1.04. The company has a current ratio of 12.25, a quick ratio of 12.25 and a debt-to-equity ratio of 0.03.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. Analysts expect that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC grew its stake in shares of Eupraxia Pharmaceuticals by 429.7% during the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after purchasing an additional 1,289,005 shares in the last quarter. Jupiter Topco LLC purchased a new position in Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $6,851,000. Seven Fleet Capital Management LP acquired a new position in Eupraxia Pharmaceuticals in the first quarter valued at $5,137,000. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals in the 1st quarter valued at $5,068,000. Finally, Rubric Capital Management LP purchased a new position in shares of Eupraxia Pharmaceuticals during the 1st quarter worth approximately $5,004,000.

Top Eupraxia Pharmaceuticals Stories

Here are a few of the latest stories about EPRX:

  • Positive Sentiment: Cantor Fitzgerald and Oppenheimer each initiated or reiterated a Buy view on EPRX, adding to positive analyst coverage. Cantor Fitzgerald Buy rating Oppenheimer Buy rating
  • Positive Sentiment: HC Wainwright kept its Buy rating and $16 price target, raising its estimates for fiscal 2026 and 2028 and moving its 2030 forecast from a loss to a profit. HC Wainwright estimate updates
  • Negative Sentiment: HC Wainwright lowered its fiscal 2027 and 2029 EPS forecasts, while the company reported a wider third-quarter loss—risks that temper the positive analyst news. Analyst estimates Quarterly loss report

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.

Recommended Stories

Analyst Recommendations for Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.